The corporate venture arm of Germany’s Merck Serono SA is collaborating with Compugen Ltd. to establish a new company, Neviah Genomics Ltd., which will discover, develop and market novel biomarkers for drug toxicity.
Announced June 25, the Neviah collaboration is the first investment under Merck Serono Ventures’ Israel Bioincubator program, established by Merck...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?